206.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$203.11
Aprire:
$203.14
Volume 24 ore:
120.88K
Relative Volume:
0.14
Capitalizzazione di mercato:
$22.81B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
22.73
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
+5.68%
1M Prestazione:
+5.57%
6M Prestazione:
+17.15%
1 anno Prestazione:
+15.36%
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, NTRA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
DGX
Quest Diagnostics Inc
|
206.04 | 22.48B | 11.28B | 1.07B | 1.33B | 9.0657 |
|
TMO
Thermo Fisher Scientific Inc
|
511.60 | 182.91B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
195.88 | 133.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
567.54 | 43.32B | 4.45B | 1.10B | 1.06B | 13.59 |
|
A
Agilent Technologies Inc
|
137.79 | 37.18B | 7.23B | 1.41B | 1.09B | 4.979 |
|
NTRA
Natera Inc
|
267.36 | 37.23B | 2.50B | -226.32M | 71.51M | -1.6412 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 83/100 - GuruFocus
Quest Diagnostics Receives New York Clearance for Haystack MRD Test - marketscreener.com
New York clears Quest Diagnostics' cancer recurrence test statewide - Stock Titan
Quest Diagnostics updates 2025 guidance, shares trade near record valuation levels - Ad-hoc-news.de
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? - TradingView
Quest Diagnostics Prevails in Appeal Over 401(k) Fund Options - Bloomberg Law News
Quest Diagnostics StockWeekly outlook with earnings ahead - AD HOC NEWS
Is Quest Diagnostics Stock Underperforming the S&P 500? - inkl
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics - Yahoo Finance
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026 - GuruFocus
Quietly smarter diagnostics, Quest Diagnostics Quanum Enterprise Content Manager streamlines lab wor - AD HOC NEWS
Quest Diagnostics Inc (DGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quest Diagnostics Inc (DGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quest Diagnostics Inc (DGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Quest Diagnostics Inc (DGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quest Diagnostics Inc (DGX) Institutional Confidence - TradingKey
Quest Diagnostics Inc (DGX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quest Diagnostics Inc (DGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quest Diagnostics Inc (DGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quest Diagnostics Inc (DGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quest Diagnostics sets July 23 call for second-quarter results - Stock Titan
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report - Quest Diagnostics Newsroom
$21M in discounted Quest lab tests, aid for firefighters and cancer cluster - Stock Titan
Health Coalition Issues Open Letter to Health Minister to Stop Transfer of Lab Testing by Quest/Lifelabs to U.S. - GlobeNewswire Inc.
Quest Diagnostics Stock (US74834L1008): Analyst Actions Shape Monday Focus After Quiet Newsflow - AD HOC NEWS
Quest Diagnostics Stock (US74834L1008): Stock in focus after calm trading and no fresh catalyst - AD HOC NEWS
Quest Diagnostics Stock (US74834L1008): Valuation in focus after a quiet week - AD HOC NEWS
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history - Yahoo Finance UK
Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential - ChartMill
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 - GuruFocus
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare - Yahoo Finance
TD Asset Management Inc Sells 65,893 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score o - GuruFocus
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score of 83 Tells Investors - GuruFocus
Quest Diagnostics stock: Analyst estimates & ratings - MSN
4 Outpatient Home Health Stocks Benefiting From Industry Trends - TradingView
Fox Run Management L.L.C. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Purchased by Cibc World Market Inc. - MarketBeat
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Quest Diagnostics (DGX) Stock Analysis: Strong Upside Potential With Analyst Consensus - DirectorsTalk Interviews
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 7,700 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Bank of New York Mellon Corp Has $116.39 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
[144] QUEST DIAGNOSTICS INC SEC Filing - Stock Titan
How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes - Yahoo Finance
BNP Paribas Financial Markets Purchases 6,487 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):